Genmab and AbbVie’s Epkinly has met its dual primary endpoints as a second-line combination therapy in relapsed/refractory follicular lymphoma (FL).

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older adults after a benefit-risk reevaluation, though the move comes with an ...

MAXONA Pharmaceuticals has submitted an IND application seeking approval from the US FDA for its lead compound, MAX-001, to treat acute pain.

Linked data could unlock essential hidden insights across healthcare – but linking has to be executed correctly to avoid ...

CorMedix, a biopharmaceutical company specialising in critical care products, is to acquire Melinta Therapeutics for $300m.

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo Nordisk.

Bayer disclosed that its Q2 earnings were inflated by transfer fees at its German football club Bayer Leverkusen.

The health secretary has halted the development of 22 mRNA vaccine projects by BARDA while stopping all future schemes.

Astria has made an exclusive licensing agreement with Kaken for the development and commercialisation rights of navenibart in Japan.

Primary packaging is never an afterthought in the world of injectable drugs, where systems such as vials, syringes, and ...

The FDA has approved a label expansion to Teva’s Ajovy in certain children and adolescents, making it the first migraine prevention drug of its kind in the age group.

Discontinuation rates in pediatric trials remain high, reflecting logistical and clinical obstacles. To overcome these hurdles, clinical research organizations can assist - re-thinking pediatric trial ...